All
Impact of childhood atopic dermatitis
April 6th 2017Instructional handouts help caregivers stick to complicated treatment plans for pediatric AD patients. Historically effective AD treatments are being augmented with new phosphodiesterase inhibitors and biologics. Gentler approaches such as massage, light therapy, and melatonin may also be of value for children with AD.
TNF inhibitor treatment tactics
April 6th 2017With a long history in dermatology and rheumatology, TNF inhibitors can not only improve psoriasis and psoriatic arthritis, but they also may reduce comorbid cardiovascular risks and work better combined with methotrexate. Low doses of cyclosporine may be effective at treating the psoriasis reaction when topicals have proven ineffective. Aggressively managing TNF-induced reactions can help patients stay on drugs that are working for other challenging diseases.
Genetic testing for melanoma risk
April 5th 2017Patients who carry a high-penetrance melanoma predisposition gene can often benefit from screening for other cancers. Patients who receive a positive genetic test result are more likely to embrace prevention and detection measures. A new “Rules of Three” proposes a point-based guideline to help determine who should be referred for genetic counseling and testing.
Targeted treatments for atopic dermatitis
March 16th 2017Emerging treatments are expected to help fill the need for safer and more effective therapies for atopic dermatitis (AD). Both systemic and topical treatments are needed to provide full and complete treatment for patients with AD. Targeting the specific axis or axes that control AD may contribute to developing personalized approaches to treatment
Therapies for hidradenitis suppurativa
March 16th 2017TNF inhibitors adalimumab and infliximab have evidence-based efficacy for the treatment of hidradentitis suppurativa (HS). Anti-interleukin inhibitors ustekinumab and anakinra also being evaluated in small studies for treatment of HS. Antibiotics, hormones, retinoids, steroids and laser therapies directly targeting the lesions round out an effective treatment plan for HS patients.
Understanding and using biosimilars
March 16th 2017Biosimilars have the potential to lower the high costs of biologic treatments for patients suffering from chronic skin diseases. Although biosimilars have received FDA approval derms still have many questions about what they are and when they may be used appropriately. Patent wars and a lack of rules and regulations at the state level add to the confusion about using biosimilars.
Advances in lasers, light sources
March 16th 2017Laser and light source treatments target many of the most common skin conditions that dermatologists encounter. The recent expansion in laser dermatology is both promising and exciting as the treatments available to derms and their patients continue to grow. New technologies are taking laser and light source treatments in new directions of skin structure imaging, epidermal harvesting, tissue rejuvenation, and new types of photodynamic therapies.
Fractional resurfacing and the standard of care
March 10th 2017It is important to note that where there are two or more recognized methods of diagnosing or treating the same condition, a physician does not fall below the standard of care by using any of the acceptable methods even if one method turns out to be less effective than another method.